Sublingual immunotherapy in children modulates allergen-induced in vitro expression of cytokine mRNA in PBMC
Article first published online: 31 AUG 2006
Volume 61, Issue 10, pages 1184–1190, October 2006
How to Cite
Savolainen, J., Jacobsen, L. and Valovirta, E. (2006), Sublingual immunotherapy in children modulates allergen-induced in vitro expression of cytokine mRNA in PBMC. Allergy, 61: 1184–1190. doi: 10.1111/j.1398-9995.2006.01206.x
- Issue published online: 31 AUG 2006
- Article first published online: 31 AUG 2006
- Accepted for publication 16 June 2006
- allergic rhinitis;
- specific immunotherapy;
- Th1 cells;
- Th2 cells;
- regulatory T cell
Background: During subcutaneous immunotherapy (SCIT), there is a local mucosal shift from Th2 to Th1 type cytokine predominance and downregulation of interleukin (IL)-5 and eosinophilia. According to recent studies IL-10- and transforming growth factor (TGF)-β-induced tolerance is another key phenomenon in SCIT. Few data to date is available on mechanisms and roles of these cytokines in sublingual immunotherapy (SLIT).
Scope: This study was undertaken to analyse the allergen-induced in vitro mRNA expression of IL-4, IL-5, IL-10, TGF-β and interferon (IFN)-γ during SLIT in peripheral blood mononuclear cells (PBMC) of children with allergic rhinitis (AR).
Methods: Ten patients with AR undergoing pollen SLIT with a weekly dose of 200 000 SQ-U, 10 with a weekly dose of 24 000 SQ-U of glycerinated mixture of Betula verrucosa, Corylus avellana and Alnus glutinosa and 10 with placebo were included in the study. Peripheral blood mononuclear cell samples were collected and stimulated with pollen allergen extract prior to the treatment, after 1 and 2 years of the treatment. The cytokine mRNA expression was assessed using kinetic real time reverse transcription polymerase chain reaction (RT-PCR; TaqMan®).
Results: The in vitro allergen-induced mRNA expression of IL-5 by PBMC in the placebo group at 1 (P = 0.0065) and 2 (P = 0.013) years of therapy were increased in comparison with the highest dose. The expression of IL-10 mRNA was increased in the highest dose group (P = 0.0016) and the lower dose group (P = 0.034) at 2 years of therapy when compared with placebo. The change in the expression of allergen-induced TGF-β had an inversed correlation with the change of IL-5 (r = −0.38, P = 0.036) and positive correlation with the change of IL-10 (r = 0.58, P = 0.0019).
Conclusions: Sublingual immunotherapy induced a dose-dependent systemic allergen-specific immunological response in children with AR. During high-dose SLIT, there was activation of regulatory cytokine IL-10 and an inhibitory effect on IL-5 expression increase that was associated with TGF-β.